Podcast: Navigating pharma-digital therapeutic alliances

The industry is at a unique crossroads: pharmaceutical and digital therapeutic (DTx) companies have begun to act on their ambition to advance digital therapeutics—but the path to successful alliances and, importantly, scale remains uncertain. As a follow up to our recent research on building pharma-DTx alliances, we sat down with two leaders to get their perspective on:

• The dos and don’ts of pharma-DTx partnerships
• Evidence standards for digital therapeutics
• Channel pathways and business models for DTx companies
• Assessing the value of working with pharma as a DTx company

Hear from ZS’ Paul Darling, Novo Nordisk’s Amy West, Pear Therapeutics’ Corey McCann, and Rock Health’s Megan Zweig in our latest podcast episode.